Great news everyone!
Pfizer's senior vice president for global research and development said Tuesday that the pharmaceutical company's pipeline remains robust, with three major candidates preparing for final federal drug review next year.
Toni Hoover, who also serves as director of Pfizer's New London and Groton campuses, told a breakfast meeting of the Chamber of Commerce of Eastern Connecticut that the company expects to seek approval of pharmaceuticals to treat cholesterol, HIV-AIDS and malaria in 2007.
Hoover said the drug candidates include a combination torcetrapib/Lipitor cholesterol medication; Maraviroc, an HIV-AIDS treatment; and a combination of Zithromax and chloroquine to treat malaria.
“No other company has the track record of innovation that Pfizer has,” Hoover told the chamber gathering at the Radisson Hotel. “We have very exciting agents targeted for the treatment of some devastating illnesses.”
That's great Toni. Have a pay hike.
PS, dont mention the 300 job losses at Groton.
Sources: The Day , Boston Globe
No comments:
Post a Comment